Key Takeaways
- VenoStent has raised $16M in Series A funding.
- The funds will be used to advance the development of their bioresorbable, smart polymers.
- The lead investors for this round were Good Growth Capital and IAG Capital Partners.
Texas-based biomaterials company, VenoStent, recently secured $16 million in a Series A funding round. This brings the company’s total funding to over $22 million. The funding announcement can be found on their Crunchbase profile.
VenoStent is paving the way in the Advanced Materials, Biotechnology, Health Care, Life Science, and Medical Device industry with their innovative development of bioresorbable, smart polymers dedicated to transforming vascular surgery.
The funding round, which took place on July 31, 2023, was led by Good Growth Capital and IAG Capital Partners. Other investors that took part in the round include Alumni Ventures, Baylor Angel Network, Cowtown Angels, Creative Ventures, SNR.vc, and TMC Venture Fund. This is the ninth fundraising round for VenoStent.
With the newly acquired funds, VenoStent aims to further develop and bring to market its transformative products that aim to push the boundaries in vascular surgery and make significant improvements in patient care in the Health Care and Biotechnology industries.
Ready to amplify your reach and engage with the most dynamic community in the venture world? Consider sponsoring an article with us. Learn more about our promotional opportunities and sponsored articles here.
Your story could be the next big hit on US Venture News!
Follow Us